PN Renewed in DOD Bill

The Foundation for Peripheral Neuropathy is pleased to announce that peripheral neuropathy has been renewed as an eligible condition for Department of Defense (DOD) funds for the upcoming year. The Bill recently made it into law and FPN is proud that its lobbying campaign this past year was a success!

Peer-Reviewed Medical Research Program

The agreement provides US$370,000,000 for a peer-reviewed medical research program.

Research areas considered under this funding are restricted to: arthritis, cardiomyopathy, congenital heart disease, diabetes, dystonia, eating disorders, viral diseases, endometriosis, epidermolysis bullosa, familial hypercholesterolemia, fibrous dysplasia, focal segmental glomerulosclerosis, food allergies, Fragile X, frontotemporal degeneration, Guillain-Barre syndrome, hemorrhage control, hepatitis B, hydrocephalus, hypercholesterolemia, hypertension, inflammatory bowel diseases, interstitial cystitis, malaria, mitochondrial disease, myalgic encephalomyelitis/chronic fatigue syndrome, myotonic dystrophy, nephrotic syndrome, non-opioid therapy for pain 145 management, nutrition optimization, pathogen-inactivated blood products, peripheral neuropathy, plant-based vaccines, platelet like cell production, polycystic kidney disease, pressure ulcers, pulmonary fibrosis, respiratory health, Rett syndrome, rheumatoid arthritis, sleep disorders and restriction, suicide prevention, sustained release drug delivery, trauma, vascular malformations, women’s heart disease, Ehlers-Danlos syndrome, pancreatitis, musculoskeletal disorders related to acute and chronic bone conditions and injuries, and Friedreich’s ataxia.

Thank you

To everyone who supported FPN’s lobbying efforts, thank you. This is a huge win for peripheral neuropathy research!

To learn how you can continue to help our efforts, please contact FPN at [email protected].

Leave a Comment

Send this to a friend